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Post-transplantation cytomegalovirus (CMV) syndrome can be prevented using the antiviral drug
(val)ganciclovir. (Val)ganciclovir is typically administered following a prophylactic or a pre-emptive
strategy. Theprophylactic strategy entails early universal administration, thepre-emptive strategy,
early treatment in case of infection. However, it is not clear which strategy is superior with respect
to transplantationoutcome; sex-specificeffects of theseprevention strategies are not known.We
have retrospectively analyzed 540 patients from themulti-centre Harmony study along eight pre-
defined visits: 308 were treated according to a prophylactic, 232 according to a pre-emptive
strategy. As expected, we observed an association of prophylactic strategy with lower incidence
of CMV syndrome, delayed onset and lower viral loads compared to the pre-emptive strategy.
However, in female patients, the prophylactic strategy was associated with a strong impairment
of glomerular filtration rate one year post-transplant (difference: −11.8 ± 4.3mlmin−1·1.73m−2,
p  0.006). Additionally, we observed a tendency of higher incidence of acute rejection and
severe BK virus reactivation in the prophylactic strategy group. While the prophylactic strategy
was more effective for preventing CMV syndrome, our results suggest for the first time that the
prophylactic strategymight lead to inferior transplantation outcomes in female patients, providing
evidence for a strong association with sex. Further randomized controlled studies are necessary
to confirm this potential negative effect.
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INTRODUCTION
Cytomegalovirus (CMV) is a herpesvirus often reported as the
most important viral pathogen after kidney transplantation
(Elfadawy et al., 2013; Le Page et al., 2013; Fehr et al., 2015). It
is a major cause of morbidity and mortality, being associated
with retinitis, pneumonitis, colitis, encephalitis, allograft
damage and allograft loss, among others (Egli et al., 2007;
Elfadawy et al., 2013; Le Page et al., 2013; Fehr et al., 2015).
CMV syndrome or disease may occur as a consequence of
reactivation of latent infections or through primary infection,
acquired from the donor or from the environment (Fehr et al.,
2015). The major risk factor for CMV syndrome or disease is
the pre-transplantation serostatus: CMV seronegative
transplant recipients with a seropositive donor (D+R−) have
the highest risk, while seropositive recipients (R+) have an
intermediate risk and seronegative recipients with
seronegative donors (D−R−) have the lowest risk (Fehr
et al., 2015). Moreover, the use of immunosuppressive drugs
like rabbit antithymocyte globulin (ATG) can additionally
increase the incidence of CMV (re)activations (Malvezzi
et al., 2015).
The standards in prevention and treatment of CMV (re)
activation are based on ganciclovir or its oral prodrug
valganciclovir (KDIGO Transplant Work Group, 2009;
Kotton et al., 2018). In addition to antiviral therapy, CMV-
specific T cell immunity has been shown to control CMV viral
reactivations, determining the outcome of disease (Sester et al.,
2001; Bunde et al., 2005; Egli et al., 2008). Two prevention
strategies are routinely employed in the clinic: prophylactic and
pre-emptive (KDIGO TransplantWork Group, 2009; Fehr et al.,
2015; Kotton et al., 2018). The prophylactic strategy is based on
the universal administration of (val)ganciclovir for patients with
a CMV risk constellation, usually during 3–6 months after
transplantation (KDIGO Transplant Work Group, 2009;
Kotton et al., 2018). In the pre-emptive strategy, patients are
regularly monitored for CMV through quantitative polymerase
chain reaction (qPCR) or pp65 antigenemia test; (val)
ganciclovir is only administered after a positive test, ideally
before any symptoms of CMV syndrome or disease manifest
(KDIGO Transplant Work Group, 2009; Kotton et al., 2018).
The pre-emptive strategy thus leads to a reduction of
unnecessary treatments, which is advantageous with respect
to the appearance of side effects and resistances against antiviral
drugs (KDIGO Transplant Work Group, 2009; Kotton et al.,
2018).
While the KDIGO guideline of 2009 preferred prophylaxis
as the standard of prevention, the more recent reference CMV
management guideline recommends both strategies for the
prevention of CMV disease in patients with both high or
intermediate CMV mismatch-based risk constellation
(KDIGO Transplant Work Group, 2009; Kotton et al.,
2018). However, the differences in outcome with regard to
other criteria, including renal function and other viral (re)
activations is largely unclear. Interestingly, there is evidence of
sex differences in both ganciclovir pharmacokinetics and the
anti-CMV immune response (Villacres et al., 2004; Perrottet
et al., 2009; Di Benedetto et al., 2015; Hassan et al., 2016;
Stranzinger et al., 2016; Fleck-Derderian et al., 2017; Momper
et al., 2017; Lindemann et al., 2018). Thus, female patients have
been shown to have a faster ganciclovir clearance, and distinct
anti-CMV immunological profiles, e.g., higher number of IL-
21 secreting anti-CMV T cells (Villacres et al., 2004; Perrottet
et al., 2009; Di Benedetto et al., 2015; Momper et al., 2017;
Lindemann et al., 2018). In spite of this, there are to our
knowledge still no studies on the influence of sex on the clinical
outcomes of CMV prevention strategies. In this work, we
provide first tentative evidence that prophylaxis might be




As part of the systems medicine project e:KID, we conducted
a sub-study within the randomized, multi-centre,
investigator-initiated Harmony trial (NCT 00724022)
(Thomusch et al., 2016; Blazquez-Navarro et al., 2018) to
determine the impact of CMV prevention strategy on
transplant outcome. For this, CMV, Epstein-Barr virus
(EBV) and BK virus (BKV) viral loads, white blood cell
count and creatinine were measured at predetermined
eight study visits (Blazquez-Navarro et al., 2018). This
viral monitoring was non-interventional and centrally
performed and was independent from the internal,
interventional viral monitoring (see Patient Monitoring).
The study was carried out in compliance with the
Declaration of Helsinki and Good Clinical Practice.
Patient Medication
According to study design, patients were treated with a
quadruple (arm A) or triple (arms B and C)
immunosuppressive therapy (Thomusch et al., 2016). Patients
in arm A received an induction therapy with basiliximab and
maintenance therapy consisting of tacrolimus (Advagraf ®,
Astellas), mycophenolate mofetil (MMF) and corticosteroids.
Patients in arm B received the same treatment as in arm A, but
corticosteroids were withdrawn at day 8. Patients in arm C
received the same treatment as in arm B, except induction was
achieved with ATG, instead of basiliximab. The study protocol
proposed furthermore that patients with a D+R− for either CMV
or CMV, as well as patients in arm C regardless of their
mismatch, should receive a valganciclovir prophylaxis
(Thomusch et al., 2016).
Patient Monitoring
Patients were monitored for transplantation outcomes during the
first post-transplantation year. Graft function was monitored
along seven visits, scheduled at the second week, first month,
second month, third month, sixth month, ninth month, and 12th
month. To assess graft function, glomerular filtration rate was
calculated using the CKD-EPI formula, measured in
mL·min−1·1.73 m−2 (Levey et al., 2009). Serious adverse
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events were defined following the Good Clinical Practice
guidelines. Suspected episodes of acute rejection had to be
confirmed through biopsy; histologic characteristics were
described according to the Banff criteria of 2005 (Solez
et al., 2007). Regarding the outcome assessment, acute
rejection was analyzed excluding borderline rejections.
Routine surveillance biopsies were allowed but not mandatory.
Clinical Monitoring and Management of
Clinical Complications
Viral (re)activations were monitored during the first post-
transplantation year and managed at local centers as
described previously (Blazquez-Navarro et al., 2018). CMV
in particular was monitored for all patients, independently of
the prevention strategy. Monitoring was performed
independently from the above described CMV viral load
measurements and was based on three different methods:
serum PCR viral load measurements; test for pp65
antigenemia and symptom monitoring according to the
internal center standards. Diagnosis of CMV syndrome was
likewise based on these methods, where a qPCR over 1,000
copies·mL−1 was defined as positive. Patients with CMV
syndrome were treated based on internal center standards.
Suggested treatment was (val)ganciclovir treatment according
to local standards with/or without reduction of tacrolimus and
MMF dose. No data on the time point of CMV syndrome
diagnostic were available for this study; no data on CMV disease
were available.
Screening of CMV, EBV and BKV Viraemia
In parallel to the clinical monitoring performed at each
center, peripheral blood samples from the seven post-
transplant visits as well as a pre-transplant visit were
centrally monitored for CMV, EBV and BKV by TaqMan
qPCR, as described previously (Blazquez-Navarro et al.,
2018). The centralized viral load assessment was non-
interventional.
Definition of CMV Prevention Strategy
Groups and Characterization of Antiviral
Treatments
Patients were stratified into two prevention strategy groups based
on the (val)ganciclovir treatments during the first 14 days. All
patients that started a (val)ganciclovir treatment during the first
14 days were assigned into the prophylactic strategy group; the
rest of the sub-cohort was classified in the pre-emptive strategy
group. The 14 days threshold was chosen to allow comparability
with our previous prospective study on the topic (VIPP), in which
recruiting took place during the first two post-transplant weeks
(Witzke et al., 2012; Witzke et al., 2018). CMV syndrome was
treated equally for both strategy groups, as explained above.
Antiviral treatments with no data on the end time point were
considered for the calculation of valganciclovir average daily dose,
even though they cannot be included in the calculation of the
duration of treatment. The average daily dose refers to the
period(s) in which the patient received a valganciclovir
treatment, not the entire first post-transplant year.
Accordingly, reported MMF dose and tacrolimus
concentration/dose (C/D) ratio correspond to the 14 days
threshold.
Viraemia-Based Patient Classification
To assess the efficacy of prevention strategies regarding viral (re)
activations, patients were classified based on their peak viral load
values for CMV, EBV and BKV, as previously published
(Blazquez-Navarro et al., 2018). Briefly, the classifications are
defined as follows: “detectable viral load” corresponds to patients
with at least one viral load measurement over detection limit (250
copies·mL−1) (Blazquez-Navarro et al., 2018), “elevated viral
load” to patients with at least one viral load measurement over
2000 copies·mL−1, “high viral load” to patients with at least one
viral load measurement over 10,000 copies·mL−1. These groups
overlap with each other.
Descriptive Statistics and Baseline Analysis
Categorical variables are summarized here as numbers and
frequencies; quantitative variables are reported as median and
interquartile range (IQR). Differences between the groups were
calculated using Pearson’s chi-square test with continuity
correction (or two-tailed Fisher’s exact test, when stated); odds
ratios (OR) and 95% confidence intervals (95% CI) are provided.
In all cases, odds ratio over one denote a higher prevalence of the
adverse event in the pre-emptive strategy group. Differences in
quantitative variables between groups were analyzed using the
two-tailed Mann-Whitney test. Kaplan-Meier curves for time to
occurrence of the first CMV (re)activation were calculated using
the R survival package (version 2.43–3); strategy groups were
compared using the log-rank test. Correlations are reported
employing Spearman’s rho and p value). Box plots depict the
median, first and third quartile of a variable; the maximum length
of the whiskers corresponds to 1.5 times the IQR.
In baseline analysis, a p value below 0.050 was considered
significant. For descriptive statistics, p values are reported purely
for illustrative reasons – no definition of statistical significance is
employed.
Multi-Parameter Regression Modeling
To determine the influence of prevention strategies, sex and their
interaction on transplantation outcomes, we performed multi-
parameter regression controlling for confounders: The regression
models used for the analysis incorporate as independent variables
the prevention strategies, sex and their interaction term, as well as
all selected confounding factors, and as dependent variable the
outcome of interest. For categorical binary outcomes, logistic
regression was employed, for continuous outcomes linear
regression was used. The choice of confounders was
performed through backward elimination by Akaike’s
information criterion starting from a full model, as the criteria
for the allocation to a prevention strategy are unknown so that a
selection based on medical criteria is not possible. The full
model incorporated – apart from prevention strategies, sex and
their interaction – all measured demographic factors (see
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Table 1 and Supplementary Table S1) and the transplantation
center. For the analysis of the eGFR one year after
transplantation (eGFR-1y), CMV, BKV and EBV peak viral
loads and acute rejection were additionally included as potential
confounders, as these events preceded or were simultaneous to
eGFR-1y and might hence have an influence on it. Peak viral
loads were included in the models as log-transformed (base 10);
viral loads below detection level were set to zero. All analyses
were run on complete cases, without performing imputation.
Thus, the multiparameter analysis of viral reactivation and
eGFR-1y was performed on patients with available
measurements one year after transplantation.
After backward elimination, the resulting model for each
outcome was tested for multi-collinearity and (in the case of
linear regression) for homoscedasticity: Multi-collinearity was
assessed calculating the generalized variance-inflation factor,
with a threshold of five to exclude a factor. Homoscedasticity
was evaluated with the studentized Breusch-Pagan test; if it
cannot be assumed (p < 0.050), robust standard errors are
reported. The resulting model for each outcome is provided
in the Supplementary Table S2. The p values for the
independent variables of the final model were calculated
employing the t test.
In the multi-parameter analysis, a p value below 0.050 was
considered significant. p values were not corrected for
multiple testing, as this study was of exploratory nature
(Bender and Lange, 2001; Velentgas et al., 2013; Li et al.,
2017).
RESULTS
Definition of Study Sub-cohorts
To assess the effects of CMV prevention strategy on
transplantation outcome, we retrospectively analyzed the
cohort of an existent study (N  540 patients from 18 centers)
with a female ratio of 35.9% (N  194) (Thomusch et al., 2016;
Blazquez-Navarro et al., 2018). Patients were grouped into two
sub-cohorts, based on whether they started an antiviral therapy
during the first two post-transplant weeks (prophylactic strategy
group, N  308) or not (pre-emptive strategy group, N  232) (see
Definition of CMV Prevention Strategy Groups and
Characterization of Antiviral Treatments). As described
previously, viral load (CMV, EBV and BKV), graft function
and other clinical markers were collected along eight visits
during the first post-transplant year; a total of 3,715 blood
samples were analyzed (Blazquez-Navarro et al., 2018).
In this work, we have evaluated the effects of prevention strategy
and sex on themain outcome eGFR-1y and the secondary outcomes,
incidence of acute rejection, CMV complications, and BKV and EBV
(re)activations. The analyses were performed based on the following
approach: For descriptive purposes, single-parameter differences
between sub-cohorts were assessed; multi-parameter regression
analysis – controlling for all potential confounders – was
employed to determine any effects of prevention strategy, sex and
their interaction on transplantation outcomes. After an assessment
of the baseline characteristics of the sub-cohorts, we describe in detail
the most important findings in the next sections.
TABLE 1 | Differences in patient baseline characteristics between strategy groups.





Female sex 104 (33.8%) 90 (38.8%) 0.265
Caucasian race 304 (98.7%) 231 (99.6%) 0.397a
Recipient age (years) 55 [46–64] 57 [44–64] 0.988
Body mass index (kg·m−2) 26.3 [23.5–29.7] 25.4 [22.8–28.4] 0.059
CMV mismatch-based risk High (D+R−) 119 (39.1%) 27 (12.1%) <0.001
Medium (R+) 137 (45.1%) 129 (57.8%)
Low (D−R−) 48 (15.8%) 67 (30.0%)
EBV mismatch-based risk High (D+R−) 13 (5.1%) 11 (6.2%) 0.583a
Medium (R+) 239 (93.4%) 161 (91.0%)
Low (D−R−) 4 (1.6%) 5 (2.8%)
Donor age (years) 55 [48–65] 55 [46–65] 0.931
No previous transplantations 298 (96.8%) 216 (94.7%) 0.346
Living donor 31 (10.1%) 35 (15.4%) 0.088
Expanded criteria donor 136 (44.2%) 99 (42.7%) 0.798
High donor serum creatinine (>1.5 mg dL−1) 35 (11.4%) 39 (16.8%) 0.090
Cold ischemia time (min) 626 [427–844] 600 [414–840] 0.505
Number of HLA A, B and DR mismatches 3 [2–4] 3 [1–4] 0.457
Panel-reactive antibodies before transplantation 23 (7.6%) 17 (7.7%) 1.000
White blood cell count (cells·L−1) 7.2 [5.7–8.9] 7.1 [6.0–8.5] 0.676
Therapy arm A (basiliximab + steroids) 93 (30.2%) 96 (41.4%) <0.001
B (basiliximab) 92 (29.9%) 83 (35.8%)
C (ATG) 123 (39.9%) 53 (22.8%)
Low MMF daily dose (<2000 mg·day−1) 37 (12%) 45 (19.4%) 0.025
Tacrolimus C/D level (ng·mL−1·mg−1·kg·day) 65.6 [43.6–99.2] 63.7 [42.9–92.2] 0.341
aData are given as number (percentage) ormedian [interquartile range]. Expandedcriteria donors are definedas follows: ageover 60 years or ageover 50 years and at least twoof the following factors:
cerebrovascular accident as the cause of death, hypertension or a serum creatinine level over 1.5 mg dL−1. p value is calculated based on Pearson’s chi-square test or Fisher’s exact test for binary
variables (marked witha) and based on Mann-Whitney test for continuous variables. Data on the cause of end-stage kidney disease are summarized in Supplementary Table S1.
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Study Sub-cohorts Characteristics
To identify differences at baseline between the two prevention
strategy sub-cohorts regarding demographics or treatment
procedures, we performed comparative statistics (see
Table 1, for cause of end-stage kidney disease see
Supplementary Table S1). As shown in Table 1, significant
(p < 0.050) differences were found for MMF daily dose, CMV
mismatch-based risk and therapy arm; the difference was
highly significant (p < 0.001) for the latter two factors;
specifically among female patients a significant difference in
body mass index and CMV mismatch was found, but not in
therapy arm nor MMF daily dose (see Supplementary Table
S3). The differences in CMV risk and therapy arm are in
conformance with the study protocol; the MMF dose was
significantly associated with the different transplantation
centers (Kruskal-Wallis’ p  0.002).
59 patients (25.4%) of the pre-emptive strategy group were
treated with (val)ganciclovir after the second post-transplantation
week. In total, 367 patients (68.0%) received (val)ganciclovir during
the first post-transplant year, independently of their prevention
strategy group; use of antivirals in both groups is shown in Table 2.
As expected, valganciclovir treatments in patients of the pre-emptive
strategy cohort were significantly shorter and had significantly
higher daily doses than in the prophylactic strategy group. The
latter is in conformance with current guidelines, which recommend
for pre-emptive treatments of CMV viral load a valganciclovir dose
twice as high as for prophylaxis (Kotton et al., 2018).
Regarding differences in antiviral treatment or outcomes
between female and male patients, we observed no differences
between sexes (Table 3).
Prophylactic Strategy Group Was
Associated With a Serious Impairment of
Graft Function in Female Patients
A descriptive analysis showed that patients in the prophylactic
strategy group had, in general, a poorer transplantation course than
those in the pre-emptive strategy group, with a higher incidence of
total serious adverse events (64.6% vs. 54.3%, p  0.020, OR: 0.65
[0.45–0.94]). For the main outcome, renal function, single-
parameter analysis likewise revealed a difference between the
prevention groups. Thus, eGFR-1y was lower in the prophylactic
strategy group compared to the pre-emptive group (45.6
[33.5–58.3] vs. 50.3 [38.1–64.5] ml·min−1.1.73 m−2, p  0.011).
Of note, the difference in eGFR was noticeable for all visits from the
third post-transplant month on (Supplementary Figure S1).
Importantly, the impairment of eGFR-1y in the prophylactic
group was only observed for female patients, with a difference of
18.5 ml min−1·1.73 m−2 (38.4 [28.8–53.6] vs. 56.8 [41.3–67.9]
ml min−1.1.73m−2, p < 0.001). Among male patients, the
prophylactic strategy group had a slightly higher median eGFR-
1y (48.5 [36.3–61.5] vs. 47.2 [37.2–59.6] ml min−1.1.73m−2, p 
1.000). A difference in eGFR for females could be observed already
one month after transplantation (Figure 1).
Multi-parameter regression incorporating all potential
confounders confirmed a significant, strong association of the
interaction term prophylactic strategy:female sex with decreased
eGFR-1y (estimate: −11.8 ± 4.3 ml min−1.1.73 m−2, p  0.006);
TABLE 2 | Antiviral treatment details for the two strategy groups.






Median time under (val)ganciclovir (days) 118 [87–182] 92 [46–155] 0.006
Valganciclovir average daily dose (mg·day−1) 277 [165–450] 450 [205–454] <0.001
Patients treated with intravenous ganciclovir 32 (10.4%) 8 (13.6%) 0.623
Data are given as number (percentage) or median [interquartile range].
TABLE 3 | Differences between sexes in treatment characteristics and outcomes
of the first post-transplantation year.
Variables Male
patients (N = 346)
Female





204 (59%) 104 (53.6%) 0.265
Pre-emptive strategy group
treated with (val)ganciclovir
40 (11.6%) 19 (9.8%) 0.626
Median time under (val)
ganciclovir (days)
113 [84–177] 107 [85–181] 0.868
valganciclovir average daily
dose (mg·day−1)
328 [187–450] 362 [193–450] 0.619
Patients treated with
intravenous ganciclovir
27 (7.8%) 13 (6.7%) 1.000
Outcomes
Serious adverse event 204 (59.0%) 121 (62.4%) 0.493
eGFR-1y 48.2 [36-5–61.4] 46.8 [33.3–58.8] 0.341




57 (16.5%) 35 (18.0%) 0.730
Elevated viral load 24 (6.9%) 15 (7.7%) 0.866
High viral load 13 (3.8%) 5 (2.6%) 0.629
Syndrome 78 (22.5%) 35 (18.0%) 0.261
BKV Detectable viral
load
173 (50.0%) 87 (44.8%) 0.289
Elevated viral load 76 (22.0%) 45 (23.2%) 0.825
High viral load 41 (11.8%) 18 (9.3%) 0.438
EBV Detectable viral
load
74 (21.4%) 35 (18.0%) 0.414
Elevated viral load 28 (8.1%) 9 (4.6%) 0.178
High viral load 9 (2.6%) 2 (1.0%) 0.343a
aData are given as number (percentage) or median [interquartile range]. p value is
calculated based on Pearson’s chi-square test or Fisher’s exact test for binary variables
(marked witha) and on Mann-Whitney test for continuous variables. For the definition of
(re)activation severity degrees see Viraemia-Based Patient Classification. As it can be
observed, there were no differences between sexes with respect to (val)ganciclovir
treatments and the measured outcomes.
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while no significant association was found for prevention strategy
(p  0.651) or sex alone (p  0.138). For more details on the multi-
parameter regression model, see Supplementary Table S2A. As a
tendency toward lower eGFR in females under the prophylactic
strategy (see Figure 1B) was already observed two weeks after
transplantation (eGFR-2w), we tested additionally the possibility
of a difference in baseline conditions as the cause for the observed
association. Therefore, we repeated the analysis incorporating
eGFR-2w as a confounder (Supplementary Table S2B).
Remarkably, in spite of the highly significant correlation of
eGFR-2w with eGFR-1y (0.45 ± 0.04, p < 0.001), the negative
effect of prophylactic strategy:female sex was consistently strong
(−10.4 ± 3.7 ml min−1.1.73 m−2, p  0.005). We additionally
repeated the analysis excluding patients with a D−R- CMV
constellation (N  115), finding a similar effect in spite of the
reduction in patient number (−9.8 ± 4.0 ml min−1.1.73 m−2, p 
0.016; see Supplementary Table S2C). In conclusion, we did not
find any evidence of spuriousness of the observed effect of
prophylactic strategy:female sex on the eGFR-1y.
We further investigated the nature of the difference in eGFR
between prevention strategies in female patients, examining the
associations of daily dose and beginning of therapy with eGFR-1y.
We did not observe any negative effect of high daily doses: We
compared the female patients in the pre-emptive strategy group
that received a valganciclovir treatment, with those in the
prophylactic strategy group, as the first group had a higher
daily dose than the second (p  0.041). Thus, we observed
that these patients had a higher eGFR-1y than those in the
prophylactic group (38.4 [28.8–53.6] vs. 57.7 [40.1–66.6]
ml·min−1.1.73 m−2, p  0.005), in spite of the higher
valganciclovir dose. On the other hand, we observed an effect
of therapy timing in eGFR-1y, with a positive correlation between
day of treatment beginning and eGFR-1y (ρ  0.27, p  0.015)
among female patients who received (val)ganciclovir.
The Prophylactic Strategy Was Associated
With Significantly Lower CMV Viral Loads
and Incidence of Syndrome Than the
Pre-emptive Strategy
We further evaluated the effectivity of the strategies in the
prevention of CMV complications. The single-parameter,
descriptive analysis showed a higher incidence of CMV viral
load in the pre-emptive strategy group (19.8% vs. 14.9%, p 
0.167); for CMV syndrome a higher incidence was found in the
prophylactic strategy group (see Supplementary Table S4A). The
latter was not unexpected, as most patients with high CMV risk
were in the prophylactic strategy group (see Table 2). Stratifying
for CMV risk, a clear trend for lower incidence of CMV (re)
activation was observed in the prophylactic strategy group; but
not for CMV syndrome (Supplementary Table S4B). However,
the results of the multi-parameter regression (Supplementary
Tables S2D,E) show that prophylactic strategy had a significant
association with both lower peak CMV viral load (-0.63 ± 0.20
log10 (copies·mL−1), p  0.002) and CMV syndrome incidence
(-1.45 ± 0.63, p  0.020). No significant sex effects, nor
interactions between prevention strategy and sex were
observed for these outcomes.
Interestingly, CMV incidence showed different temporal
patterns in the two strategy groups (Figure 2): While in the
pre-emptive strategy group 86.7% of all CMV load events
occurred in the first 100 days post-transplant, in the
prophylactic strategy group it was only 56.1% (Figure 2A).
Moreover, a higher prevalence of detectable CMV viral load
FIGURE 1 | Box plot of the graft function dynamics of the prevention strategy groups stratified for sex. The numbers indicate the p value of the difference in eGFR
between the prevention strategy groups, as calculated using the Mann-Whitney test. The p values for the first six measurements are included only to facilitate
understanding on the eGFR dynamics, and are therefore not adjusted for multiple testing.
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was observed in the prophylactic strategy group for all study visits
after the third month (Figure 2B).
There Was a Tendency Toward Higher
Incidence of Acute Rejection and BKV
Reactivation Among Patients Under
Prophylactic Strategy
Regarding the important complication acute rejection, a
tendency toward higher incidence was found in the
prophylactic strategy group (14.9% vs. 6.0%, p  0.002, OR:
0.37 [0.18–0.70]). However, the multi-parameter analysis
(Supplementary Table S2F) could not confirm this tendency,
as only a borderline significant association of prophylactic
strategy group with rejection (−0.83 ± 0.51, p  0.100) was
observed; there was no evidence of an effect of sex, nor of the
interaction with prevention strategy.
Regarding the effects of prevention strategy for other
viruses, no evidence of an effect of prevention strategy was
found for EBV, neither through (stratified) single-parameter
analysis (Supplementary Tables S4A,C), nor through multi-
parameter analysis (Supplementary Table S2G).
Furthermore, there was no evidence of sex-specific effects.
On the other hand, we found a higher incidence of severe BKV
(re)activation in patients of the prophylactic strategy group
(p  0.056, OR: 0.55 [0.29–1.01]), see Supplementary Table
S4A. The multi-parameter analysis (Supplementary Table
S2H) showed likewise a borderline significant association of
prophylactic strategy with higher BKV viral loads (0.51 ± 0.29
log10 (copies·mL−1), p  0.084), while no effect of sex could be
observed.
DISCUSSION
The goal of our study was to evaluate the clinical efficacy and sex-
associated differences of two common CMV prevention strategies in
a large cohort of kidney transplant patients from the multi-centre
Harmony study. The main finding of the study is the first tentative
evidence suggesting superiority of the pre-emptive strategy in female
patients with respect to graft function (Small et al., 2005; Khoury
et al., 2006; Kliem et al., 2008; Spinner et al., 2010; VanDer Beek et al.,
2010; Witzke et al., 2012; Florescu et al., 2014; Meije et al., 2014;
Witzke et al., 2018). The observed effect was very large,
corresponding to an increase of 11.8 ± 4.3 ml min−1.1.73m−2 in
eGFR-1y. This is especially relevant, as eGFR-1y is an accepted
marker for long term transplantation outcomes (Kasiske et al., 2011).
Even after controlling for differences in eGFR observed two weeks
after transplantation (at a time point in which effects of prevention
strategy are already thinkable), the effect of prevention strategy
among female patients remained consistently strong. However,
due to the inherent limitations of a retrospective, non-randomized
study, the interpretation of this potential effect requires caution.
Interestingly, our results highlight the importance of sex-
associated effects in transplantation. In recent years, sex
differences have emerged as an essential factor in clinical
studies (Rásky et al., 2017). In transplantation, several
complications are associated with sex, including acute
rejection, graft loss and viral (re)activations (Meier-Kriesche
et al., 2001; Hirsch et al., 2013; Momper et al., 2017;
Lindemann et al., 2018). However, the underlying reasons for
these sex differences are not well understood; possible causes
include the hormonal regulation of the immune system, the
effects of pregnancy, and differences in the metabolism of
FIGURE 2 | Incidence of CMV (re)activation in the prevention strategy groups during the first post-transplant year. (A) Kaplan-Meier curves for absence of CMV (re)
activation during the first post-transplant year. CMV (re)activation was defined as viral load over detection limit. Prevention strategy groups were compared using the
log-rank test. (B) Prevalence of CMV viral load over detection limit for each of the eight protocol visits.
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drugs routinely employed in transplantation (Momper et al., 2017).
For example, there is tentative evidence of sex-related differences in
the pharmacokinetics of (val)ganciclovir (Perrottet et al., 2009;
Momper et al., 2017). Thus, ganciclovir clearance has been
observed to be 24% faster in female transplantation patients,
suggesting higher activity of the organic anion transporter 1
(Perrottet et al., 2009; Momper et al., 2017). Furthermore, it has
been shown repeatedly that women and men have different anti-
CMV immunological profiles: (Villacres et al., 2004; Di Benedetto
et al., 2015; Lindemann et al., 2018) Thus, Lindemann et al. have
observed that these different immunological profiles may have an
influence on the graft function, as they observed an association of
high numbers of IL-21-secreting anti-CMV T cells with both female
sex and lower eGFR in a clinical transplantation context (Lindemann
et al., 2018). While none of these two observations provide a direct
explanation for the observed effect of (val)ganciclovir prophylaxis on
eGFR-1y, they demonstrate that further sex-associated differences
for pharmacokinetics and pharmacodynamics, anti-CMV immune
response and their consequences on renal function are conceivable.
Our analyses may provide some evidence on the nature of the
hypothetical negative effect of prophylactic strategy on eGFR-1y.
Although the impaired graft function in the female prophylactic
strategy group can be partly explained through the higher incidence
of BKV severe (re)activation and rejection, the results of the multi-
parameter analysis suggest an independent association of prevention
strategy with graft function, regardless of these adverse events
(Salvadori et al., 2006; Schwarz et al., 2012; Blazquez-Navarro
et al., 2018). Therefore, our results do not support the hypothesis
that these adverse events are the main cause for the difference in
eGFR-1y between sub-cohorts. Regarding possible nephrotoxic
effects of the antiviral drug, we did not find any association of
higher valganciclovir doses with lower eGFR–rather, the opposite
association was observed – in contrast to Heldenbrand et al
(Heldenbrand et al., 2016). The absence of a negative dose-
dependent effect suggests that the observed difference was not a
consequence of nephrotoxicity of valganciclovir. On the other hand,
the time of beginning of the (val)ganciclovir therapy could be
determinant for the eGFR-1y: We observed a positive correlation
between time of beginning of (val)ganciclovir treatment and eGFR
(i.e. the later patients began the therapy, the higher the renal
function). This correlation could also explain the positive
association of antiviral dose with eGFR-1y, as patients receiving a
higher valganciclovir dose as part of a pre-emptive treatment had
later treatments compared to the prophylactic strategy.
Albeit being highly speculative, we hypothesize that the
observed results may be (at least in part) caused by an
immunological mechanism. As we demonstrated in a previous
study, an increased number of CMV-specific T-cells upon CMV
(re)activation is associated with reduced alloreactivity and
improved graft function in renal transplantation patients
(Nickel et al., 2009). Similarly, in liver transplantation,
primary CMV infection has been found to be associated with
donor-specific CD8+ T-cell hyporesponsiveness and increased
Vδ1/Vδ2 γδ T-cell ratio – a surrogate marker for operational
tolerance (Shi et al., 2015). Accordingly, the higher rate of
asymptomatic CMV (re)activation found in the pre-emptive
strategy group could potentially lead to regulatory γδ T-cell-
based graft protection and explain the better graft function and
lower incidence of acute rejection. Therefore, an early
administration of (val)ganciclovir would potentially hinder the
development of this protective immune response. Importantly,
this hypothesis does not contradict the commonly encountered
association between CMV and acute rejection, which was in fact
also observed in our patient cohort (Blazquez-Navarro et al.,
2018). Rather, it suggests a direction for this effect, with acute
rejection or its treatment as a cause of CMV reactivation, rather
than a consequence. This in line with the literature, since the
hypothetical negative effects of CMV on acute rejection remain
highly controversial, while the opposite has been observed in
several recent studies (Dickenmann et al., 2001; Erdbruegger
et al., 2012; Feng et al., 2016; Felipe et al., 2019; Jorgenson
et al., 2019).
Our hypothesis would also explain the observed positive
correlation between day of beginning of antiviral therapy and
renal function, as according to this premise only the early
administration would have negative consequences on the
building of the protective immune response. This hypothesis is
compatible with the observed differences between male and
female recipients, as sex-associated differences in the anti-
CMV immunity have been shown to correlate with graft
function (Lindemann et al., 2018). This observation shows
how sex and anti-CMV immunity could potentially interact
and affect eGFR (Lindemann et al., 2018). Therefore, further
research, including systems medicine approaches, is needed to
better understand the effects of CMV prevention strategies from
an immune, virological and pharmacokinetic point of view – with
emphasis on sex-associated differences–and their effects on
transplantation outcome (Maier et al., 2017; Blazquez-Navarro
et al., 2018).
Of interest, the prophylactic strategy group had a higher
incidence of late-onset CMV (from the sixth month on); such
increases of viral (re)activation incidence after the end of
prophylaxis have been observed before (Khoury et al., 2006;
Florescu et al., 2014). We also observed a tendency toward
higher incidence of rejection and severe BK virus (re)
activation among patients in the prophylactic strategy group,
although these tendencies could not be confirmed through multi-
parameter analysis. While we have already reported a negative
effect of prophylaxis on rejection within the VIPP study–albeit
only for the D−R+ subgroup–this study would be the first to
suggest such an association in the entire cohort (Witzke et al.,
2012;Witzke et al., 2018). Regarding BKV, the observed pattern is
in line with three recent studies (Reischig et al., 2015; Reischig
et al., 2018; Reischig et al., 2019). This effect could be explained
through the increased incidence of acute rejection among patients
in the prophylactic strategy group, as episodes of acute rejection
and anti-rejection treatment have been associated with BKV
reactivation (Schold et al., 2009; Borni-Duval et al., 2013).
On the other hand, we did not observe any effect of prevention
strategy on EBV (re)activation. This is relevant, as there is currently
no consensus in the literature on this topic. Even though a number of
publications have observed an effect against EBV or post-transplant
lymphoproliferative disease (the main EBV-associated
complication), a meta-study with 2,366 participants saw no effect
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 5346818
Blazquez-Navarro et al. Anti-CMV Prophylaxis May Lower eGFR
of prophylaxis for this EBV complication (Funch et al., 2005;
Aldabbagh et al., 2016; Cameron et al., 2017).
This study is based on the prospective Harmony study, a
trial designed with the goal of identifying which
immunosuppressive drug combination is superior with
respect to acute rejections and secondary to a number of
other outcome variables, including graft function and viral
(re)activations (Thomusch et al., 2016). A shortcoming of
the present study is the fact that prevention strategy groups
were not randomized, and no power calculation was performed
with respect to this question. Even though we have controlled
for all measured demographic factors in the analyses and other
potential confounding factors–including the first measured
eGFR after transplantation–we cannot exclude bias, for
example in unmeasured factors such as sex-mismatch, as the
cause of the observed differences. A further limitation is related
to the criteria employed for deciding the prevention strategy for
each patient: As the decision to adopt a prophylactic or a pre-
emptive strategy was taken by each individual physician or
center, it is difficult to ascertain the background, especially if
the decision differs from what would be expected based on the
study protocol. This could potentially introduce unknown bias
in the use of prevention strategies. On the other hand, our study
does have some advantages: We have analyzed a larger (N 
540) and more heterogeneous cohort (patients with all CMV
mismatch-based risk constellations) than most studies on the
matter, thereby achieving higher statistical power (Khoury
et al., 2006; Kliem et al., 2008; Spinner et al., 2010; Van Der
Beek et al., 2010; Witzke et al., 2012; Florescu et al., 2014;
Witzke et al., 2018). Moreover, our study design could be
viewed as closer to clinical reality, with similar
valganciclovir doses and prophylaxis duration to those
routinely employed in the clinic (Rissling et al., 2018). Based
on the limitations of the study, we deem our results as evidence
that further research is needed to determine the effects of
prevention strategies on transplantation outcome and their
hypothetical interactions with sex.
In summary, our study provides the first tentative evidence in the
literature suggesting superiority of the pre-emptive approach in female
patients. Even though the prophylactic strategy was associated with
reduced prevalence of CMV (re)activation and syndrome, we also
found a potential associationwith a strong renal function impairment.
The effects of prevention strategy on graft function were found in the
multi-parameter analysis to be independent from all potential
confounders for which there were available data. Moreover, we
observed tentative evidence of a sex-independent tendency toward
higher incidence of acute rejection and BKV (re)activation.
Importantly, further studies are needed to confirm these
observations: Based on our results, randomized controlled studies
comparing pre-emptive and prophylactic strategy for the end-point
eGFR-1y–stratifying for sex–are paramount. Moreover, observational
studies analyzing the potential relationship between time of beginning
of the valganciclovir therapy and the renal function could further shed
light on the matter.
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